184 related articles for article (PubMed ID: 35672415)
21. Modulation of androgen receptor by FOXA1 and FOXO1 factors in prostate cancer.
Zhao Y; Tindall DJ; Huang H
Int J Biol Sci; 2014; 10(6):614-9. PubMed ID: 24948874
[TBL] [Abstract][Full Text] [Related]
22. GATA2 negatively regulates PTEN by preventing nuclear translocation of androgen receptor and by androgen-independent suppression of PTEN transcription in breast cancer.
Wang Y; He X; Ngeow J; Eng C
Hum Mol Genet; 2012 Feb; 21(3):569-76. PubMed ID: 22021428
[TBL] [Abstract][Full Text] [Related]
23. FoxA1 specifies unique androgen and glucocorticoid receptor binding events in prostate cancer cells.
Sahu B; Laakso M; Pihlajamaa P; Ovaska K; Sinielnikov I; Hautaniemi S; Jänne OA
Cancer Res; 2013 Mar; 73(5):1570-80. PubMed ID: 23269278
[TBL] [Abstract][Full Text] [Related]
24. FOXP1 is an androgen-responsive transcription factor that negatively regulates androgen receptor signaling in prostate cancer cells.
Takayama K; Horie-Inoue K; Ikeda K; Urano T; Murakami K; Hayashizaki Y; Ouchi Y; Inoue S
Biochem Biophys Res Commun; 2008 Sep; 374(2):388-93. PubMed ID: 18640093
[TBL] [Abstract][Full Text] [Related]
25. Cell-line and tissue-specific signatures of androgen receptor-coregulator transcription.
Bebermeier JH; Brooks JD; DePrimo SE; Werner R; Deppe U; Demeter J; Hiort O; Holterhus PM
J Mol Med (Berl); 2006 Nov; 84(11):919-31. PubMed ID: 16932916
[TBL] [Abstract][Full Text] [Related]
26. A test of the pioneer factor hypothesis using ectopic liver gene activation.
Hansen JL; Loell KJ; Cohen BA
Elife; 2022 Jan; 11():. PubMed ID: 34984978
[TBL] [Abstract][Full Text] [Related]
27. Nucleosome dynamics define transcriptional enhancers.
He HH; Meyer CA; Shin H; Bailey ST; Wei G; Wang Q; Zhang Y; Xu K; Ni M; Lupien M; Mieczkowski P; Lieb JD; Zhao K; Brown M; Liu XS
Nat Genet; 2010 Apr; 42(4):343-7. PubMed ID: 20208536
[TBL] [Abstract][Full Text] [Related]
28. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
29. Multifaceted interaction between the androgen and Wnt signaling pathways and the implication for prostate cancer.
Terry S; Yang X; Chen MW; Vacherot F; Buttyan R
J Cell Biochem; 2006 Oct; 99(2):402-10. PubMed ID: 16741972
[TBL] [Abstract][Full Text] [Related]
30. Noncanonical Wnt signaling mediates androgen-dependent tumor growth in a mouse model of prostate cancer.
Takahashi S; Watanabe T; Okada M; Inoue K; Ueda T; Takada I; Watabe T; Yamamoto Y; Fukuda T; Nakamura T; Akimoto C; Fujimura T; Hoshino M; Imai Y; Metzger D; Miyazono K; Minami Y; Chambon P; Kitamura T; Matsumoto T; Kato S
Proc Natl Acad Sci U S A; 2011 Mar; 108(12):4938-43. PubMed ID: 21383160
[TBL] [Abstract][Full Text] [Related]
31. Androgen receptor signaling in androgen-refractory prostate cancer.
Grossmann ME; Huang H; Tindall DJ
J Natl Cancer Inst; 2001 Nov; 93(22):1687-97. PubMed ID: 11717329
[TBL] [Abstract][Full Text] [Related]
32. ΔNp63 is a pioneer factor that binds inaccessible chromatin and elicits chromatin remodeling.
Yu X; Singh PK; Tabrejee S; Sinha S; Buck MJ
Epigenetics Chromatin; 2021 Apr; 14(1):20. PubMed ID: 33865440
[TBL] [Abstract][Full Text] [Related]
33. Increased Akt signaling resulting from the loss of androgen responsiveness in prostate cancer.
Dulinska-Litewka J; McCubrey JA; Laidler P
Curr Med Chem; 2013; 20(1):144-57. PubMed ID: 23033951
[TBL] [Abstract][Full Text] [Related]
34. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
Murthy S; Agoulnik IU; Weigel NL
Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
[TBL] [Abstract][Full Text] [Related]
35. A noncanonical AR addiction drives enzalutamide resistance in prostate cancer.
He Y; Wei T; Ye Z; Orme JJ; Lin D; Sheng H; Fazli L; Jeffrey Karnes R; Jimenez R; Wang L; Wang L; Gleave ME; Wang Y; Shi L; Huang H
Nat Commun; 2021 Mar; 12(1):1521. PubMed ID: 33750801
[TBL] [Abstract][Full Text] [Related]
36. Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer.
Sahu B; Laakso M; Ovaska K; Mirtti T; Lundin J; Rannikko A; Sankila A; Turunen JP; Lundin M; Konsti J; Vesterinen T; Nordling S; Kallioniemi O; Hautaniemi S; Jänne OA
EMBO J; 2011 Sep; 30(19):3962-76. PubMed ID: 21915096
[TBL] [Abstract][Full Text] [Related]
37. Integration of regulatory networks by NKX3-1 promotes androgen-dependent prostate cancer survival.
Tan PY; Chang CW; Chng KR; Wansa KD; Sung WK; Cheung E
Mol Cell Biol; 2012 Jan; 32(2):399-414. PubMed ID: 22083957
[TBL] [Abstract][Full Text] [Related]
38. Androgen receptor and chemokine receptors 4 and 7 form a signaling axis to regulate CXCL12-dependent cellular motility.
Hsiao JJ; Ng BH; Smits MM; Wang J; Jasavala RJ; Martinez HD; Lee J; Alston JJ; Misonou H; Trimmer JS; Wright ME
BMC Cancer; 2015 Mar; 15():204. PubMed ID: 25884570
[TBL] [Abstract][Full Text] [Related]
39. GLUT12 promotes prostate cancer cell growth and is regulated by androgens and CaMKK2 signaling.
White MA; Tsouko E; Lin C; Rajapakshe K; Spencer JM; Wilkenfeld SR; Vakili SS; Pulliam TL; Awad D; Nikolos F; Katreddy RR; Kaipparettu BA; Sreekumar A; Zhang X; Cheung E; Coarfa C; Frigo DE
Endocr Relat Cancer; 2018 Apr; 25(4):453-469. PubMed ID: 29431615
[TBL] [Abstract][Full Text] [Related]
40. Control of androgen receptor signaling in prostate cancer by the cochaperone small glutamine rich tetratricopeptide repeat containing protein alpha.
Buchanan G; Ricciardelli C; Harris JM; Prescott J; Yu ZC; Jia L; Butler LM; Marshall VR; Scher HI; Gerald WL; Coetzee GA; Tilley WD
Cancer Res; 2007 Oct; 67(20):10087-96. PubMed ID: 17942943
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
